Drug Trial Radar · NCT05425446
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
Last checked: Nov 19, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Sep 19, 2022
Primary completion
Aug 9, 2024
Study completion Jan 17, 2025
Sponsor
- Lead sponsor
- Chugai PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.
Conditions
- Celiac Disease
Interventions
DONQ52Drug
Subcutaneous (SC) injection
PlaceboDrug
Subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higherTime frame: Up to 246 days
- Safety as assessed by Vital signs (blood pressure, body temperature, pulse rate, respiratory rate, percutaneous oxygen saturation)Time frame: Up to 246 days
- Safety as assessed by Electrocardiograms (ECGs; QT interval, heart rate)Time frame: Up to 246 days
- Safety as assessed by Laboratory tests (hematology, blood chemistry, coagulation and urinalysis)Time frame: Up to 246 days
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Pinnacle Research Group
Anniston, Alabama
Mountain View Clinical Research
Denver, Colorado
Jacksonville Center for Clinical Research
Jacksonville, Florida
Clinical Site Partners
Leesburg, Florida
Clinical Site Partners - Orlando
Winter Park, Florida
Velocity Clinical Research - Boise
Meridian, Idaho
Tandem Clinical Research
Marrero, Louisiana
Mayo Clinic - Rochester
Rochester, Minnesota
Long Island Gastrointestinal Research Group
Great Neck, New York
Columbia University Medical Center
New York, New York
Lucas Research - Diabetes & Endocrinology Consultants, PC
Morehead City, North Carolina
North Carolina Clinical Research
Raleigh, North Carolina
Aventiv Research, Inc.
Columbus, Ohio
Digestive Specialists Inc
Dayton, Ohio
Velocity Clinical Research, Anderson
Anderson, South Carolina
Alliance for Multispecialty Research
Knoxville, Tennessee
Digestive Research of Central Texas
Waco, Texas
Care Access Research
Ogden, Utah
Campbelltown Hospital
Campbelltown, New South Wales, Australia
University of Sunshine Coast Clinical Trials Centre - Morayfield
Morayfield, Queensland, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.